Merck and Eisai's Keytruda/Lenvima combo fails PhIII trials for melanoma, colorectal cancer
Since 2018 — when Merck and Eisai kicked off their collaboration to combine and test out Keytruda and Lenvima against multiple cancers — the two-drug combo has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.